Novartis AG PE Ratio 2006-2018 | NVS

Current and historical PE ratio for Novartis AG (NVS) from 2006 to 2018. The price to earnings or PE ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. The current PE ratio for Novartis AG (NVS) as of March 31, 2018 is 16.06.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $92.417B $49.109B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $337.885B 16.15
Pfizer (PFE) United States $222.399B 13.69
Merck (MRK) United States $168.539B 15.06
AbbVie (ABBV) United States $142.740B 14.56
Novo Nordisk (NVO) Denmark $121.712B 20.17
Sanofi (SNY) France $105.114B 13.31
GlaxoSmithKline (GSK) United Kingdom $100.888B 13.79
Eli Lilly (LLY) United States $97.070B 19.27
AstraZeneca (AZN) United Kingdom $93.793B 9.82
Bristol-Myers Squibb (BMY) United States $92.417B 18.18